J.Mike McCune, MD, PhD

Photo of J.Mike McCune, MD, PhD

Email J.Mike
(415) 206-8101

1001 Potrero Ave
San Francisco, CA 94110

Visit CTSI Profile

  • Professor, UCSF School of Medicine
  • Member, CFAR Scientific Council

Biography

Mike McCune is a professor of medicine and chief of the Division of Experimental Medicine at the University of California, San Francisco (UCSF). He received his AB degree from Harvard College in 1975, his PhD degree from Rockefeller University in 1981, and his MD degree from Cornell University Medical College in 1982. He completed his residency in internal medicine in 1984 and did fellowship training in infectious diseases at UCSF. He is board certified in internal medicine.

After post-doctoral work at Stanford in the Department of Pathology in 1988, Dr. McCune was a founder and the chief executive officer of SyStemix, Inc., where he then served as vice president, research and development, until 1991. Thereafter and until his move to the UCSF-affiliated Gladstone Institute of Virology and Immunology in 1995, he was vice president of the New Enterprise Research Division, an exploratory research group; a member of the Partnership Committee of Progenesys, a joint venture that he founded between SyStemix and Sandoz aimed at developing hematopoietic stem cell–based gene therapies for HIV disease; and a clinical associate at UCSF working at the San Francisco General Hospital AIDS clinic.

Dr. McCune's research focuses on the definition of pathogenic mechanisms of viral diseases, particularly HIV-1 disease. This focus has spanned a range of fields, from understanding critical structural determinants of infectivity (McCune et al., Cell 1988) to devising a small animal model (the SCID-hu Thy/Liv mouse) to study HIV pathogenesis and to prioritize antiretroviral compounds against HIV (McCune et al., Science 1988a, 1988b, 1990) to studying mechanisms of T cell depletion and repletion in vivo (Bonyhadi et al., Nature 1993; Su et al., Immunity 1995; Komanduri et al., Nature Medicine 1998; Hellerstein et al., Nature Medicine 1998; Stoddart et al., Nature Medicine 2001; McCune Nature 2001).

Throughout this body of work, he has engaged in hypothesis-driven, patient-oriented research that involves collaborative teams of basic scientists, translational researchers, and clinicians. Most recently, and as a consequence of a sabbatical year at the Institut Pasteur (2003-2004), he has devoted all of his attention to understanding the correlates of protective immunity against HIV, with the specific intent to work with others to develop an effective vaccine. This change of focus has now been materialized at UCSF by the creation of the Division of Experimental Medicine, of which Dr. McCune is the chief.

Dr. McCune’s studies have led to the publication of over 160 peer-reviewed articles, and he is the holder of 20 patents and inventions. He is a member of many scientific and professional societies, including the American Society for Clinical Investigation, the American Association of Physicians, and the Henry Kunkel Society. He has served on the editorial boards of Virology and the Journal of the Acquired Immune Deficiency Syndrome. He was awarded the Elizabeth Glaser Pediatric AIDS Foundation Scientist Award in 1996, the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research in 2000, a MERIT Award from the NIH in 2001, and the NIH Director’s Pioneer Award in 2004.

Displaying 1 - 12 of 12

  1. McCune JM. Henry Kunkel and the teaching of patient-oriented research. Clin Immunol. 2016 Nov; 172:27-28. View on Pubmed
  2. Ladell K, Hazenberg MD, Fitch M, Emson C, McEvoy-Hein Asgarian BK, Mold JE, Miller C, Busch R, Price DA, Hellerstein MK, McCune JM. Continuous Antigenic Stimulation of DO11.10 TCR Transgenic Mice in the Presence or Absence of IL-1ß: Possible Implications for Mechanisms of T Cell Depletion in HIV Disease. J Immunol. 2015 Nov 1; 195(9):4096-105. View on Pubmed
  3. Loke P, Favre D, Hunt PW, Leung JM, Kanwar B, Martin JN, Deeks SG, McCune JM. Correlating cellular and molecular signatures of mucosal immunity that distinguish HIV controllers from noncontrollers. Blood. 2010 Apr 15; 115(15):e20-32. View on Pubmed
  4. Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, Hsue P, McCune JM, Deeks SG. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010; 5(1):e8886. View on Pubmed
  5. Cheng LE, Kanwar B, Tcheurekdjian H, Grenert JP, Muskat M, Heyman MB, McCune JM, Wara DW. Persistent systemic inflammation and atypical enterocolitis in patients with NEMO syndrome. Clin Immunol. 2009 Jul; 132(1):124-31. View on Pubmed
  6. Lederer S, Favre D, Walters KA, Proll S, Kanwar B, Kasakow Z, Baskin CR, Palermo R, McCune JM, Katze MG. Transcriptional profiling in pathogenic and non-pathogenic SIV infections reveals significant distinctions in kinetics and tissue compartmentalization. PLoS Pathog. 2009 Feb; 5(2):e1000296. View on Pubmed
  7. Favre D, Lederer S, Kanwar B, Ma ZM, Proll S, Kasakow Z, Mold J, Swainson L, Barbour JD, Baskin CR, Palermo R, Pandrea I, Miller CJ, Katze MG, McCune JM. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009 Feb; 5(2):e1000295. View on Pubmed
  8. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, Peterlin BM. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem. 2009 Mar 13; 284(11):6782-9. View on Pubmed
  9. Lozano Reina JM, Favre D, Kasakow Z, Mayau V, Nugeyre MT, Ka T, Faye A, Miller CJ, Scott-Algara D, McCune JM, Barré-Sinoussi F, Diop OM, Müller-Trutwin MC. Gag p27-specific B- and T-cell responses in Simian immunodeficiency virus SIVagm-infected African green monkeys. J Virol. 2009 Mar; 83(6):2770-7. View on Pubmed
  10. Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman KP, Busch MP, Lee TH, Nixon DF, McCune JM. Maternal alloantigens promote the development of tolerogenic fetal regulatory T cells in utero. Science. 2008 Dec 5; 322(5907):1562-5. View on Pubmed
  11. Jones RB, Ndhlovu LC, Barbour JD, Sheth PM, Jha AR, Long BR, Wong JC, Satkunarajah M, Schweneker M, Chapman JM, Gyenes G, Vali B, Hyrcza MD, Yue FY, Kovacs C, Sassi A, Loutfy M, Halpenny R, Persad D, Spotts G, Hecht FM, Chun TW, McCune JM, Kaul R, Rini JM, Nixon DF, Ostrowski MA. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med. 2008 Nov 24; 205(12):2763-79. View on Pubmed
  12. Hatano H, Delwart EL, Norris PJ, Lee TH, Dunn-Williams J, Hunt PW, Hoh R, Stramer SL, Linnen JM, McCune JM, Martin JN, Busch MP, Deeks SG. Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J Virol. 2009 Jan; 83(1):329-35. View on Pubmed